Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Ovarian cancer classification system validated
Fri January 15th - A newly developed method for subtyping ovarian cancer has been validated as accurately predicting disease outcome. More
How euthanasia rates vary across The Netherlands
Fri January 15th - Regions of The Netherlands have recorded a seven-fold unexplained variation in euthanasia rates, according to new analysis published today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...

Surgery may help advanced prostate cancer

Tuesday April 15th, 2014

Men with advanced and spreading prostate cancer may benefit from surgery, a conference was told yesterday.

Swedish researchers have been testing the benefits of giving these patients prostate removal as well as hormonal drug treatment.

It had been thought that surgery would achieve little when the cancer had spread from the prostate.

But, according to the Swedish study, surgery was linked to a 60% reduction in death rates.

The researchers at the Karolinska Institute reported their findings to the conference of the European Association of Urology in Stockholm, Sweden.

The researchers reached their findings from a study of 109,000 men treated for prostate cancer over a 14 year period in Sweden.

They found two groups of 700 men with advanced prostate cancer. One group had undergone surgery or radiotherapy while the second group was given hormonal treatment only. There were 231 deaths in the first group and 93 deaths in the second group.

Dr Prasanna Sooriakumaran, of the University of Oxford, UK, one of the researchers, said a controlled study is now needed to test the findings.

He said: "Currently, men with advanced prostate cancer are treated with hormonal therapy alone, and the median survival is around five years. A number of novel agents have been proposed in recent years, and these improve survival by months.

"Our research has the potential to improve survival outcomes by more than these novel treatments, and thus could represent a major advance in the field."

Fellow researcher Professor Peter Wiklund said: “What we are presenting here is not only new but highly controversial, and will represent a paradigm shift in our understanding and management of advanced prostate cancer.

"Should the improved survival that combined treatment shown in this study be a real effect, then this could revolutionise the management of advanced prostate cancer."

* A second study reported to the conference found that men with blood group O enjoyed a reduced risk of suffering recurrence of prostate cancer.

The Tokyo Medical University research, involving 555 patients, found these men were 35% less likely than those with blood group A to suffer cancer recurrence.

Tags: Cancer | Europe | Menís Health

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)